This, too, supports the presence of at least a subset of patients exhibiting reduced stimulus-activity coupling at CCK1R, with some of these patients typical of those who were likely included in previous clinical trials for the treatment of obesity. The gene discussed is CCKAR; the disease is obesity disorder.